What GRAIL (GRAL)'s Canada Test Rollout Means For Shareholders
GRAIL to Announce Third Quarter 2026 Financial Results
GRAIL (GRAL) Stock Sees Fair Value Lift After Analysts Back Galleri Outlook
Morgan Stanley Maintains Equal-Weight on GRAIL, Raises Price Target to $120
TD Cowen Maintains Buy on GRAIL, Raises Price Target to $180
Jim Cramer Breaks Down the Stakes in Detail as GRAIL (GRAL) Awaits Its Next Big Decision
Grail (GRAL) vs Guardant Health (GH): Which is a Better Stock to Buy?
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
Jim Cramer Says This Stock Could Rise Like Moderna (MRNA)
Why GRAIL (GRAL) Is Up 12.9% After Positive FDA Panel Verdict On Galleri Trial Results
UBS Maintains Buy on GRAIL, Raises Price Target to $175
Guggenheim Maintains Buy on GRAIL, Raises Price Target to $155
Why Grail Stock Skyrocketed Nearly 70% In A Week. What To Watch Next.
GRAIL: AdCom's Vote Of Confidence Is Significant
Canaccord Genuity Maintains Buy on GRAIL, Raises Price Target to $150
Mizuho Maintains Neutral on GRAIL, Raises Price Target to $100
GRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued?
Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test
FDA Panel Endorses GRAIL Galleri Cancer Screening Tool
The Holy Grail In Cancer? FDA Panel Backs Blood Tests
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
